DrugPatentWatch Database Preview
Ipsen Inc Company Profile
What is the competitive landscape for IPSEN INC, and when can generic versions of IPSEN INC drugs launch?
IPSEN INC has two approved drugs.
There are twelve US patents protecting IPSEN INC drugs.
There are fifty-five patent family members on IPSEN INC drugs in twenty-three countries and four supplementary protection certificates in four countries.
Summary for Ipsen Inc
| International Patents: | 55 |
| US Patents: | 12 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Ipsen Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;IV (INFUSION) | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,782,349 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;IV (INFUSION) | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,724,303 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;IV (INFUSION) | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,452,162 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;IV (INFUSION) | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 8,329,213 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;IV (INFUSION) | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,339,497 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Ipsen Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ipsen Inc | INCRELEX | mecasermin recombinant | INJECTABLE;SUBCUTANEOUS | 021839-001 | Aug 30, 2005 | 5,681,814 | ➤ Try a Free Trial |
| Ipsen Inc | INCRELEX | mecasermin recombinant | INJECTABLE;SUBCUTANEOUS | 021839-001 | Aug 30, 2005 | 6,207,640 | ➤ Try a Free Trial |
| Ipsen Inc | INCRELEX | mecasermin recombinant | INJECTABLE;SUBCUTANEOUS | 021839-001 | Aug 30, 2005 | 5,824,642 | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Non-Orange Book US Patents for Ipsen Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,658,203 | Liposomes useful for drug delivery to the brain | ➤ Try a Free Trial |
| 9,737,528 | Liposomes useful for drug delivery to the brain | ➤ Try a Free Trial |
| 9,717,723 | Liposomes useful for drug delivery | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Ipsen Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Denmark | 2861210 | ➤ Try a Free Trial |
| Spain | 2632915 | ➤ Try a Free Trial |
| Israel | 235937 | ➤ Try a Free Trial |
| Brazil | 112014031088 | ➤ Try a Free Trial |
| Ukraine | 86063 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Ipsen Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0885 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: ONIVYDE - IRINOTECAN; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
| 2017000042 | Germany | ➤ Try a Free Trial | PRODUCT NAME: LRINOTECAN SUCROSOFAT-SALZ, WIE Z.B. LRINOTECAN SUCROSOFAT-SALZ IN EINEM PEGYLIERTEN LIPOSOM WIE BEISPIELWEISE EINEM LIPOSOM, DAS 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLIN, CHOLESTERIN UND N-(OMEGA-METHOXYPOLY(ETHYLENGLYKOL) (MOLEKULARGEWICHT 2000)OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYLETHANOLAMIN Z.B. IM MOLVERHAELTNIS 3:2:0,015 UMFASST.; REGISTRATION NO/DATE: EU/1/16/1130 20161014 |
| C/GB97/010 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: GENERIC NAME: IRINOTECANCHEMICAL NAME: (+)-(4S)-4,11-DIETHYL-4-HYDROXY-9-((4-PIPERIDINOPIPERIDINO)CARBONYLOXY)-1H-PYRANO (3',4':6,7) INDOLIZINO(1,2-B) QUINOLINE-3,14-(4H,12H)-DIONE,OPTIONALLY THE HYDROCHLORIDE SALT THEREOF AND OPTIONALLY THE TRIHYDRATE T; REGISTERED: FR 558822.2 19950505; FR 558823.9 19950505; FR 558824.5 19950505; FR 558825.1 19950505; UK 00012/0302 19961017; UK 00012/0303 19961017 |
| 2017 00030 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
